Published 2 days ago • loading... • Updated 12 hours ago

Mallinckrodt to take over Endo in deal valued at $6.7 billion

Mallinckrodt and Endo will merge in a deal valued at $6.7 billion to enhance their branded drug sales capabilities.
Endo shareholders will receive $80 million in cash and own 49.9% of the merged entity, with Mallinckrodt shareholders owning the remainder.
The merger is projected to generate $3.6 billion in revenue in 2025 and will include products like Endo's Aveed and Mallinckrodt's Acthar gel.
Mallinckrodt CEO Siggi Olafsson will lead the new company, expected to close in the second half of 2025, pending shareholder and regulatory approval.

Insights by Ground AI

Does this summary seem wrong?

23 Articles

All

Left

Center

Right

The Reporter

+3 Reposted by 3 other sources

Chester County-based Endo to be sold for $6.7 billion

EAST WHITELAND — Endo, a pharmaceutical company that has its global headquarters in Chester County, is being acquired by Ireland’s Mallinckrodt in a cash-and-stock deal valued at $6.7 billion. Once the transaction is completed, shareholders of the East Whiteland Township-based Endo will receive a total of $80 million in cash and own nearly 50% of the combined company. Mallinckrodt shareholders will have a stake of slightly more than 50%. The tra…

22 hours ago·Pennsylvania, United States

Read Full Article

Financial Times

Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis

Groups have resolved billions of dollars in claims for selling highly addictive painkillers

1 day ago·London, United Kingdom

Read Full Article

The Tribune

Mallinckrodt to take over Endo in deal valued at $6.7 billion - Seymour Tribune

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company. Mallinckrodt shareholders will have a stake of slightly more than 50%. The companies plan to combine their generic pharmaceutical businesses and a sterile injectables business from Endo, but they will eventual…

Mallinckrodt to take over Endo in deal valued at $6.7 billion

1 day ago·Albuquerque, United States

Read Full Article

RTÉ

Mallinckrodt and Endo to merge in near $7 billion deal

Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and US opioid litigation, have agreed to merge in a deal valued at nearly $7 billion.

1 day ago·Ireland

Read Full Article